BiotechTube

Soquelitinib + Belinostat + Pralatrexate

Phase 3Recruiting
0 views this week 0 watching⚡ Active🧪Featured in Gene & Cell Therapy Watch
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peripheral T-Cell Lymphoma, Not Otherwise Specified

Conditions

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell

Trial Timeline

Oct 2, 2024 → Jul 1, 2028

NCT ID
NCT06561048

About Soquelitinib + Belinostat + Pralatrexate

Soquelitinib + Belinostat + Pralatrexate is a phase 3 stage product being developed by Corvus Pharmaceuticals for Peripheral T-Cell Lymphoma, Not Otherwise Specified. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06561048. Target conditions include Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma.

What happened to similar drugs?

8 of 20 similar drugs in Peripheral T-Cell Lymphoma, Not Otherwise Specified were approved

Approved (8) Terminated (2) Active (11)
✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
✅Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
🔄YHD1119 + LyricaYuhanPhase 3
🔄DS-5565 + placeboDaiichi SankyoPhase 3
🔄Mirogabalin + PlaceboDaiichi SankyoPhase 3
🔄DS-5565Daiichi SankyoPhase 3
✅QUTENZA + Lidocaine + TramadolAstellas PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06561048Phase 3Recruiting

Competing Products

20 competing products in Peripheral T-Cell Lymphoma, Not Otherwise Specified

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
18
LY3857210 + PlaceboEli LillyPhase 2
35
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
43
YHD1119 + LyricaYuhanPhase 1
29
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
43
YHD1119 + LyricaYuhanPhase 1
29
YHD1119 + LyricaYuhanPhase 3
40
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
29
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
35
edoxaban + Clopidogrel + AspirinDaiichi SankyoPhase 2
35
DS-5565 + placeboDaiichi SankyoPhase 3
40
Mirogabalin + PlaceboDaiichi SankyoPhase 3
40
DS-5565Daiichi SankyoPhase 3
40
Valemetostat TosylateDaiichi SankyoPhase 2
39
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placeboAstellas PharmaPhase 2
27
QutenzaAstellas PharmaPre-clinical
26
QUTENZA + Lidocaine + TramadolAstellas PharmaApproved
43
Qutenza exposureAstellas PharmaPre-clinical
26
QUTENZAAstellas PharmaPhase 3
40
Qutenza + PregabalinAstellas PharmaApproved
43